NCT05210907View on ClinicalTrials.gov

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

August 31, 2026

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

SNUH-CD19-CAR-T

SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER